BKM120: Clinical Trials

35 trials of BKM120, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed, 7 terminated, 2 withdrawn. 35 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 135Completed 26, Terminated 7, Withdrawn 2
Phase 25Completed 3, Terminated 2

Follow BKM120: new trials by email Literature Review of BKM120 trials Research Report on BKM120

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection - Locally Advanced Solid Tumor
Phase 1CompletedAdlai Nortye Biopharma Co., Ltd.472021-09-072025-06-22
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Buparlisib, Ibrutinib, Ofatumumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Phase 1TerminatedEmory University12016-01-012019-09-03
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Buparlisib, Cisplatin, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma
Phase 1WithdrawnRoswell Park Cancer Institute2015-09-012023-04-27
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
BKM120, Nabpaclitaxel - Ovarian Cancer, Endometrial Cancer
Phase 1WithdrawnRutgers, The State University of New Jersey2015-02-012022-07-28
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT) - Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Phase 1CompletedDana-Farber Cancer Institute232014-09-292026-11-05
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
PI3K inhibitor BKM120, rituximab, Pharmacodynamics - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 1CompletedKami Maddocks, MD182014-07-212022-06-30
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
BKM120, cisplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1CompletedUniversity of California, Davis32014-07-012018-01-09
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
LEE011, BYL719, fulvestrant - Breast Cancer
Phase 1CompletedNovartis Pharmaceuticals702014-05-192020-12-17
Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
Buparlisib - Renal Impairment
Phase 1CompletedNovartis Pharmaceuticals192014-03-012020-12-09
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals432014-01-092018-05-30
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Buparlisib, Buparlisib matching placebo, Docetaxel - Squamous Non-small Cell Lung Cancer
Phase 1TerminatedNovartis Pharmaceuticals272013-10-012018-08-14
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Buparlisib, Buparlisib placebo, Carboplatin - Non-Small Cell Lunch Cancer
Phase 1TerminatedNovartis Pharmaceuticals62013-09-092018-10-11
PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
PI3K inhibitor BKM120, pemetrexed disodium, carboplatin - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Phase 1CompletedCity of Hope Medical Center92013-07-012016-09-20
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase 1 / Phase 2CompletedUniversity of Chicago122013-05-012021-10-05
Palliative Thoracic Radiotherapy Plus BKM120
BKM120 - Carcinoma, Non-Small-Cell Lung
Phase 1CompletedUniversity of Oxford212013-04-012019-08-01
A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
INC424, BKM120 - Myelofibrosis
Phase 1TerminatedNovartis Pharmaceuticals632012-12-182020-12-19
BKM120+Abiraterone Acetate for Metastatic CRPC
BKM120, Abiraterone, Prednisone - Prostate Cancer
Phase 1TerminatedDana-Farber Cancer Institute42012-11-012019-02-05
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
BKM120, Panitumumab - Metastatic Colorectal Cancer
Phase 1 / Phase 2CompletedCanadian Cancer Trials Group222012-09-062023-08-04
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
BEZ235, BKM120 - Castration-resistant Prostate Cancer
Phase 1CompletedNovartis Pharmaceuticals432012-09-012020-12-09
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
LDE225, BKM120 - Dose Escalation, Safety
Phase 1CompletedNovartis Pharmaceuticals1202012-07-012020-12-19

Showing 20 of 35. Sign in to see all of them.

Conditions studied

Breast Neoplasms (7)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Colorectal Neoplasms (4)  ·  Glioblastoma (3)  ·  Neoplasm Metastasis (3)  ·  Brain Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Colonic Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Gliosarcoma (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)

Sponsors

Novartis Pharmaceuticals (15)  ·  Dana-Farber Cancer Institute (2)  ·  Emory University (2)  ·  Roswell Park Cancer Institute (2)  ·  Adlai Nortye Biopharma Co., Ltd. (1)  ·  Canadian Cancer Trials Group (1)  ·  City of Hope Medical Center (1)  ·  Kami Maddocks, MD (1)  ·  M.D. Anderson Cancer Center (1)  ·  Rutgers, The State University of New Jersey (1)  ·  SCRI Development Innovations, LLC (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University of California, Davis (1)  ·  University of Chicago (1)  ·  University of Kansas Medical Center (1)

Countries

United States (27)  ·  Spain (11)  ·  Canada (7)  ·  Germany (7)  ·  United Kingdom (7)  ·  Belgium (6)  ·  France (6)  ·  Italy (6)  ·  Netherlands (3)  ·  Australia (2)  ·  Bulgaria (2)  ·  Japan (2)  ·  Singapore (2)  ·  South Korea (2)  ·  Switzerland (2)

Top investigators

Alex Adjei (2)  ·  Autumn McRee, MD (1)  ·  Cynthia Ma (1)  ·  Darlene Gibbon, MD (1)  ·  Derek Jonker (1)  ·  Geoff Higgins, MRCP, FRCR, D.Phil (1)  ·  Glenn Bubley, MD (1)  ·  Ingrid Mayer, MD (1)  ·  Joaquina Baranda, MD (1)  ·  Jonathon Cohen, MD, MS (1)  ·  Kami Maddocks, MD (1)  ·  Karen Kelly (1)  ·  Karen Reckamp (1)  ·  Kent Shih, MD (1)

Results publications

PMID 26098748, PMID 31506897, PMID 31776899, PMID 32147671, PMID 32887722, PMID 33004905

NIH funding

2009 (2), 2008 (1)